- Home
- HDL vs XNCR Comparison
HDL vs XNCR Comparison
Compare HDL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HDL | XNCR |
|---|---|---|
| Founded | 2016 | 1997 |
| Country | Singapore | United States |
| Employees | 14003 | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 829.7M | 881.9M |
| IPO Year | N/A | 2013 |
Fundamental Metrics
Financial Performance| Metric | HDL | XNCR |
|---|---|---|
| Price | $13.40 | $11.92 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $22.33 |
| AVG Volume (30 Days) | 2.8K | ★ 648.0K |
| Earning Date | 05-20-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $125,576,000.00 |
| Revenue This Year | $14.73 | N/A |
| Revenue Next Year | $12.94 | $4.80 |
| P/E Ratio | $55.56 | ★ N/A |
| Revenue Growth | N/A | ★ 13.65 |
| 52 Week Low | $13.11 | $6.92 |
| 52 Week High | $21.21 | $18.69 |
Technical Indicators
Market Signals| Indicator | HDL | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 42.55 | 49.68 |
| Support Level | $13.31 | $10.83 |
| Resistance Level | $15.21 | $12.87 |
| Average True Range (ATR) | 0.24 | 0.58 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 16.92 | 49.60 |
Price Performance
Historical ComparisonAbout HDL SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
Super Hi International Holding Ltd is an investment holding company, and its subsidiaries are principally engaged in restaurant operations, delivery business, and sales of hot pot condiment products and food ingredients located in the overseas market outside Mainland China, Hong Kong, Macau, and Taiwan. Its mission is to become a world-wide integrated restaurant group, build the world's Chinese cuisine brand, and promote Chinese culinary heritage world-wide.
About XNCR Xencor Inc.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.